Avinger, Inc. to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company plans to participate in two upcoming investor conferences.

Avinger's management is scheduled to participate in the Evercore ISI MedTools & Outsourcing Investor Forum in Boston, MA on Thursday, December 3, 2015. Due to the one-on-one only format of the event, no webcast will be available.

Avinger's management is also scheduled to present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY on Wednesday, December 9, 2015 at 9:45am ET. Interested parties can access the live audio webcast with accompanying slides on the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.

About Avinger, Inc.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger's current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com.

CONTACT: INVESTOR CONTACT Leigh Salvo (415) 513-1281 Email: ir@avinger.com

Source:Avinger Inc.